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BACKGROUND: Deletions and duplications of the 16p11.2 BP4-BP5 locus are prevalent copy number variations
(CNVs), highly associated with autism spectrum disorder and schizophrenia. Beyond language and global cognition,
neuropsychological assessments of these two CNVs have not yet been reported.
METHODS: This study investigates the relationship between the number of genomic copies at the 16p11.2 locus
and cognitive domains assessed in 62 deletion carriers, 44 duplication carriers, and 71 intrafamilial control subjects.
RESULTS: IQ is decreased in deletion and duplication carriers, but we demonstrate contrasting cognitive proﬁles in
these reciprocal CNVs. Deletion carriers present with severe impairments of phonology and of inhibition skills beyond
what is expected for their IQ level. In contrast, for verbal memory and phonology, the data may suggest that
duplication carriers outperform intrafamilial control subjects with the same IQ level. This ﬁnding is reminiscent of
special isolated skills as well as contrasting language performance observed in autism spectrum disorder. Some
domains, such as visuospatial and working memory, are unaffected by the 16p11.2 locus beyond the effect of
decreased IQ. Neuroimaging analyses reveal that measures of inhibition covary with neuroanatomic structures
previously identiﬁed as sensitive to 16p11.2 CNVs.
CONCLUSIONS: The simultaneous study of reciprocal CNVs suggests that the 16p11.2 genomic locus modulates
speciﬁc cognitive skills according to the number of genomic copies. Further research is warranted to replicate these
ﬁndings and elucidate the molecular mechanisms modulating these cognitive performances.
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4–5 (BP4-BP5) region are among the most frequent causes of
neurodevelopmental and neuropsychiatric disorders (1–5).
Although copy number variations (CNVs) are equally and
frequently present in autism spectrum disorder (ASD) cohorts,
only duplications are associated with schizophrenia (4). Recent
studies in 16p11.2 CNV carriers demonstrated altered global
cognition in deletion carriers and duplication carriers showing,
respectively, up to 24-point and 15-point decreases in full-
scale intelligence quotient (FSIQ) compared with intrafamilial
control subjects (1,6,7). Regarding cognitive domains, language
impairment in deletion carriers was reported in several case
series (8,9), and speciﬁc assessments showed below-average
performance in comprehension, expression, and reading skills
with a 71% rate of speech and language disorder as deﬁned in& 2016 Society of B
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SEE COMMENTARDSM-IV-TR (6,10). To our knowledge, performance of duplica-
tion carriers in speciﬁc cognitive domains has not yet been
studied.
Most studies of CNVs investigated deletions and duplica-
tions separately using a case-control design; however, the
simultaneous assessment of reciprocal CNVs of the same
genomic region provides a unique opportunity to study how
the number of genomic copies (one, two, or three) may
modulate clinical phenotypes and endophenotypes. We and
other authors previously showed that body mass index
inversely correlates to the number of genomic copies at the
16p11.2 locus (1,9,11–13). The number of genomic copies is
also negatively correlated with global brain volume (14) and
associated with neuroanatomic structures involved in reward,
language, and social-cognition circuits (15).iological Psychiatry. This is an open access article under the
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Biological
PsychiatryWe hypothesized that speciﬁc cognitive skills correlate with
the number of genomic copies of the 16p11.2 region beyond
the decrease in IQ observed in both types of CNV carriers. We
also explored whether this relationship is mediated by
changes in brain structure. Our ﬁndings suggest that this
locus modulates speciﬁc cognitive domains resulting in
impaired as well as preserved or possibly enhanced skills
relative to IQ in carriers of reciprocal CNVs. Neuroimaging
analysis suggests that brain regions previously identiﬁed as
correlating with the number of genomic copies are associated
with alterations in executive functions in 16p11.2 CNV carriers.
METHODS AND MATERIALS
Participants
European Cohort. Participants were taking part in a larger
research project on CNVs at the 16p11.2 locus with the aim of
phenotyping a European cohort of 16p11.2 rearrangement
carriers. Included in our analyses were 62 deletion carriers (37
probands/25 nonproband carriers), 44 duplication carriers (21
probands/23 nonproband carriers), and 71 intrafamilial control
subjects (Table 1). Nonproband carriers are deﬁned as rela-
tives who carry the CNV identiﬁed through family cascade
testing but who were not referred for a neurodevelopmental
disorder. Inclusion criteria included presence of a recurrent
16p11.2 deletion or duplication comprising the BP4–BP5
region (29.6–30.2 Mb according to the human genome build
GRCh37/hg19). Control subjects were noncarriers in the same
families. Individuals ,3 years old were excluded from the
analyses. Also, 24 participants who were unable to perform
the cognitive tasks because of low cognitive functioning were
excluded (Supplemental Table S1).
Additional deleterious CNVs were identiﬁed in one deletion
carrier and ﬁve duplication carriers (Supplemental Table S2).
These participants were not removed from the analyses, but
their potentially confounding effects were taken into accountTable 1. Sample Characteristics
Deletion
Carriers
(n = 62)
Control
Subjects
(n = 71)
Duplication
Carriers
(n = 44)
Age, Years,
Mean 6 SD (range)
21.7 6 15.4a
(4.8–59)
34 6 15.3
(3.3–62)
28.9 6 16.8
(3.3–65)
Sex, M/F 35/27 31/40 25/19
Handedness, R/L/U 44/11/7 62/6/3 33/9/2
Inheritance, De novo/In/U 16/26/20 — 8/15/21
Kinship, Proband/
Nonproband Carriers
37/25 — 21/23
ASD, n 3 0 5
Schizophrenia, n 0 0 0
FSIQ, Mean 6 SD 72 6 13.6b 98 6 15 75 6 17.8b
NVIQ, Mean 6 SD 78 6 11.7b 99 6 15.5 76 6 15.3b
ASD, autism spectrum disorder; F, female; FSIQ, full-scale intelli-
gence quotient (standard score); In, inherited; L, left; M, male; NVIQ,
nonverbal intelligence quotient (standard score); R, right; U, unknown/
undeﬁned.
aSigniﬁcantly different from the control group, linear model,
p , .0001.
bSigniﬁcantly different from the control group, linear mixed model,
all p , .0001.
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associated with a known recurrent genomic disorder, 2)
CNVs encompassing a published critical genomic region or
disrupting a gene that is a known cause of neurodevelop-
mental disorders, or 3) rare (,1/1000) and large (.500
kb) CNVs.
The study was reviewed and approved by the local ethics
committee, and signed consent forms were obtained from
participants or legal representatives before investigation.
Participants were assessed at the Lausanne University Hos-
pital, Switzerland. Of the proband carriers, .87% were
referred to the study by the clinical geneticist who had initially
established the genetic diagnosis in the context of a neuro-
developmental disorder. Seven probands (four duplication
carriers and three deletion carriers) were identiﬁed in the
population biobank of Estonia as previously described (16),
and one duplication carrier was referred for psychiatric prob-
lems. All but four participants (n = 2 Asian descent and n = 2
African descent) were of European descent.
Simons Variation in Individuals Project Cohort. For
replication analyses on language, we used data from
the Simons Variation in Individuals Project (VIP) cohort
(http://sfari.org/resources/simons-vip), which aims at pheno-
typing carriers with a 16p11.2 BP4–BP5 rearrangement
(Supplemental Methods and Materials) (6,7).
Cognitive Assessment
Trained neuropsychologists performed all cognitive assess-
ments. Participants underwent age-appropriate and develop-
mentally appropriate neuropsychological tests assessing
overall cognitive functioning, ﬁne motor skills, language,
memory, and executive functions. All Z scores were derived
from standardized scores based on population norms pro-
vided by the testing manuals. When normative data were
unavailable, we used raw scores that were adjusted for age
and sex when appropriate. We speciﬁed the tasks where the
latter procedure was applied. We used the following psycho-
metric tests.
Overall Cognitive Functioning. The Wechsler Intelligence
Scales or Wechsler Abbreviated Scale of Intelligence (17–20)
was used to obtain FSIQ, nonverbal intelligence quotient
(NVIQ), and verbal intelligence quotient (VIQ) when available.
The FSIQ, NVIQ, and VIQ were estimated using the Differential
Ability Scales–2nd Edition (21) or the Wechsler Abbreviated
Scale of Intelligence in the VIP cohort.
Fine Motor Skills. The Purdue Pegboard test (22) ($5 years
old) assessed four conditions: dominant hand, nondominant
hand, bimanual, and assembly. Z scores were used as
dependent variables.
Language. Phonological skills were assessed with nonword
repetition ($5 years old), oromotor sequences ($3 years old),
and phonological processing ($3 years old) from the Dev-
elopmental Neuropsychological Assessment battery (23).
Age-adjusted raw scores were the dependent variables.urnal
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task including low-frequency words. The score was the
number of correct repetitions adjusted for age. Phonology in
the VIP cohort was measured by the nonword repetition
subtest ($4 years old) from the Comprehensive Test of
Phonological Processing (24), which is similar to the Devel-
opmental Neuropsychological Assessment nonword repetition
task. Age-adjusted raw score was the dependent variable.
Lexical skills were assessed with the Wechsler Vocabulary
subtest (word deﬁnition, $4 years old) and the Peabody
Picture Vocabulary Test Revised (25) (word comprehension,
$3 years old), semantic ﬂuency (animal, $3 years old), and
phonemic ﬂuency (letter M, $5 years old). For word compre-
hension and word deﬁnition tasks, Z score were used as
dependent variables, and age-adjusted raw scores were used
for verbal ﬂuencies.
Comprehension and verbal skills were assessed by selecting
24 items from the Test for Reception of Grammar 2 (26), syntax
comprehension ($15 years old), and the Wechsler Similarity
subtest ($7 years old). Z score (similarity) and age-adjusted raw
scores (syntax) were used as dependent variables. Written
language ($12 years old) was assessed through a reading task
(PC Robbery) (27) and a spelling task (Collective Spelling
Tracking) (28). Reading ﬂuency and reading comprehension
Z scores were used as dependent variables; age-adjusted and
sex-adjusted total raw scores were used for the spelling task.
Memory. Verbal short-term memory was assessed using the
forward digit span task ($6 years old) (18,19). The total age-
adjusted raw score was used as the dependent variable.
Verbal long-term memory was assessed using the California
Verbal Learning Task ($17 years old) (29). Two Z scores were
used as dependent variables: number of words correctly
recalled across all ﬁve learning trials (encoding) and number
of words recalled after a 20-minute delay (delayed recall).
Visuospatial short-term memory was assessed using the
forward spatial span task ($6 years old) (30,31). The total age-
adjusted raw score was used as the dependent variable.
Visuospatial long-term memory was assessed with the Rey-
Osterrieth Complex Figure test ($5 years old) (32). For imme-
diate and delayed (20 minutes) recalls, Z scores were used.
Executive Functions. Working memory ($6 years old) was
assessed using the backward digit span (18,19) and the
backward spatial span (30,31) tasks. The total age-adjusted
raw scores were used as dependent variables. Planning skills
were assessed with the Tower of London test ($7 years old)
(33). Z scores for total correct score and total move score were
used. The Stroop task ($8 years old) (34) was used to assess
verbal inhibition. A computerized version of the go/no-go task
($7 years old) (35) was used to assess motor inhibition. In both
tasks, Z scores for response time and number of errors
adjusted for age were used as dependent variables.
General Psychiatric and Autism Assessments
Experienced licensed psychologists and psychiatrists per-
formed the Autism Diagnostic Interview–Revised (36) and
Autism Diagnostic Observation Schedule (37) to establish a
categorical diagnosis in all participants presenting with ASDBiologicalsymptoms. All adult carriers underwent the Diagnostic Inter-
view for Genetic Studies to screen for major psychiatric
disorders (38).
Magnetic Resonance Imaging: Data Acquisition and
Processing
We used structural magnetic resonance imaging data acquired
for a previously published study (Supplemental Methods and
Materials and Supplemental Table S3) (14).Statistical Analyses
Neuropsychological Data Analyses. Variables derived
from normative data were converted into Z scores for each
participant (mean = 0; SD = 1) (Supplemental Methods and
Materials). Raw scores of variables without available normative
data were systematically adjusted for age and sex where
appropriate. We performed either linear or generalized regres-
sion analyses depending on data distribution. Cognitive
measures were the dependent variables.
To investigate the effect of CNV on cognition, we used linear
models including the following ordinal variables: deletion = 1,
control = 2, duplication = 3. For contrasts between groups, we
used post hoc t tests. Appropriate linear mixed models or
generalized linear mixed models were performed taking the
variable “family” as a random factor to account for correlated
measures within family. We also included in the statistical
design IQ, sex, and their interactions with the number of
genomic copies to control for the effects of these variables.
These additional covariates were kept in the ﬁnal models only
when the effect was signiﬁcant. Results of noncarrier partic-
ipants from deletion or duplication families were pooled, as
they did not differ in age, sex, and cognitive performances.
Selected models, estimates, and uncorrected p values are
reported in Table 2 and Supplemental Tables S4–S6.
Multiple testing correction is detailed in Supplemental
Methods and Materials. It takes into account all 34 cognitive
tests, their level of intercorrelation, and the two post hoc
contrasts (deletion carriers vs. control subjects and duplication
carriers vs. control subjects). Uncorrected p values # .001 are
considered signiﬁcant, and trends are deﬁned as .001 , p
values # .05. Statistical analyses were conducted using R
3.0.2 (The R Project for Statistical Computing; http://www.
R-project.org/).
Brain Structure and Behavior Correlation Analyses.
We tested whether the effects of CNVs on cognitive meas-
ures are mediated by changes observed in brain anatomy.
Therefore, only cognitive measures (Z scores and raw scores
adjusted for age and IQ) with signiﬁcant differences between
CNV carriers and intrafamilial control subjects were subse-
quently used for regression analysis with brain anatomy. The
statistical design also included age, sex, and total intracranial
volume as regressors. Voxel-based statistical analysis of the
gray matter (GM) regional changes was assessed by creating
voxelwise statistical parametric maps for the whole extent of
the search volume using the general linear model and random
ﬁeld theory (38). Given that the number of genomic copies
negatively correlates with GM volume in language andPsychiatry July 15, 2016; 80:129–139 www.sobp.org/journal 131
Table 2. Group Contrasts and Copy Number Variation Effect for Cognitive Measures Adjusting for IQ
Deletion Carriers vs.
Duplication Carriers
Deletion Carriers vs.
Control Subjects
Duplication Carriers vs.
Control Subjects
Copy Number
Variation
Cognitive Variables Estimatea (SE) p Value Estimateb (SE) p Value Estimateb (SE) p Value Estimate p Value
Language
Phonological skillsc
Nonword repetition (age-adjusted)d 7.27 (1.88) .0002e 210.96 (1.89) 5.2e-08e 23.68 (2.08) .078 4.1 9.9e-05e
Oromotor sequences (age-adjusted)d 10.44 (2.69) .001e 213.1 (2.68) 2.7e-06e 22.68 (2.9) .36 5.6 8e-05e
Sentence repetition (age-adjusted)d .76 (.24) .0015 2.94 (.21) 1.1e-05e 2.17 (.26) .5 .46 .0001e
Lexical skillsf
Word deﬁnition (Z score) .48 (.19) .01 2.81 (.19) 2.1e-05e 2.33 (.2) .1 .27 .0047
Comprehension and verbal skillsg
Written languageh
Reading ﬂuency (Z score) 1.7 (.52) .0015 22.1 (.48) 4.1e-05e 2.4 (.5) .44 .92 .0009e
Memory
Verbal short-term memory
Forward digit span (age-adjusted)d 1.54 (.4) .0002e 21.32 (.48) .003 .21 (.45) .64 .78 .0002e
Verbal long-term memory
CVLT encoding (sex-adjusted Z score) 1.36 (.29) 7.2e-06e 2.22 (.28) .43 1.14 (.3) .0002e .66 1.6e-05e
CVLT delayed recall (sex-adjusted Z score) 1.35 (.32) 5.9e-05e 2.03 (.31) .92 1.31 (.34) .0001e .64 .0001e
Visuospatial short-term and long-term memoryi
Executive Functions
Working memory and planningj
Inhibitionk
Stroop number of successes (age-adjusted)d .85 (.21) 4e-05e 2.78 (.17) 3e-06e .07 (.2) .72 .46 7.5e-06e
Fine Motor Skillsl
Purdue dominant hand (Z score) .56 (.26) .035 2.97 (.28) .0009e 2.41 (.29) .16 .3 .031
Purdue nondominant hand (Z score) .49 (.23) .03 21.1 (.26) 4.6e-05e 2.59 (.26) .026 .26 .035
CVLT, California Verbal Learning Test.
Linear mixed models were used to account for the correlations of measures within families. When only one family member was included in the
analysis, linear models were performed. Because of space constraints, cognitive variables showing no signiﬁcant effect of copy number variation or no
signiﬁcant group differences (c, f-l; p values corrected) are presented in Supplemental Table S5.
aPositive estimate: Deletion carrier score , duplication carrier score.
bNegative estimate: Deletion carrier or duplication carrier score , control subject score.
cPhonological processing.
dRaw score.
eSigniﬁcant p value (corrected threshold, p = .001).
fWord comprehension, semantic and phonemic ﬂuencies.
gSyntax comprehension and verbal reasoning.
hReading comprehension and spelling.
iForward spatial span and Rey-Osterrieth Complex Figure (immediate and delayed recall).
jBackward digit span, backward spatial span, and Tower of London (total correct and total move scores).
kStroop response time, go/no-go response time, and number of successes.
lPurdue: bimanual and assembly conditions.
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Psychiatryreward-related areas (14), we tested whether the behavioral
deﬁcits were associated with an increase of local GM volume.
Consequently, one-tailed t tests were used to identify the
regions whose volume showed negative correlation with the
cognitive score.
We subsequently estimated the degree of overlap between
brain areas correlating with behavioral scores and the pre-
viously identiﬁed regions sensitive to CNV (15). Clusters
sharing both effects were obtained with a subtraction of the
two statistical maps. We further examined how the number of
genomic copies interacted with the brain-behavior correlation
in these regions, using a multiple linear regression analysis of132 Biological Psychiatry July 15, 2016; 80:129–139 www.sobp.org/jothe summed voxel values for each group. For all whole-brain
analyses, we applied a voxel-level threshold of p , .05 after
familywise error correction for multiple comparisons. Trends
were assessed by using an auxiliary uncorrected voxel thresh-
old of p , .001 (39).RESULTS
Deletion carriers and duplication carriers showed cognitive
impairment (FSIQ = 72 for deletion carriers, FSIQ = 75 for
duplication carriers) compared with intrafamilial control sub-
jects (FSIQ = 98), consistent with a larger study we recentlyurnal
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Psychiatrypublished (Supplemental Table S4) (7). All verbal and non-
verbal subtests from the Wechsler Abbreviated Scale of
Intelligence equally contributed to this IQ deﬁcit
(Supplemental Figure S1). To estimate the effect of the
deletion and the duplication on speciﬁc cognitive domains
beyond their impact on general cognition, we performed all
subsequent analyses adjusting for NVIQ in verbal tasks and
FSIQ otherwise (Table 2 and Supplemental Table S5; see
Supplemental Table S6 for results not adjusted for IQ).
16p.11.2 Locus Modulates Phonology, Written
Language, and Vocabulary
The number of genomic copies positively correlated with
phonology measures such as nonword repetition (p = 9.9e-
05), oromotor sequences (p = 8e-05), and sentence repetition
(p = .0001) as well as a closely related task, reading ﬂuency (p
= .0009). This effect was mainly driven by the deletion carriers,
who performed worse than control subjects and duplication
carriers; these two latter groups did not signiﬁcantly differ
(Figure 1A–C). Word deﬁnition showed a similar trend (p =
.0047) (Table 2). Except for trends, none of the measures
assessing spelling, verbal ﬂuencies, verbal comprehension,
and verbal reasoning were signiﬁcantly affected by the
16p11.2 locus (Supplemental Table S5).
Results from the VIP data set conﬁrmed that the number of
genomic copies correlated with performance in the nonword
repetition task adjusted for NVIQ (p = 9e-6). The effect was
driven by both CNVs, with deletion carriers performing worse
than duplication carriers and intrafamilial control subjects (p =
2.7e-6 and p = .002, respectively) and duplication carriers
outperforming control subjects (p = .016) (Supplemental
Figure S2).
Verbal Short-Term and Long-Term Memory
Processes Are Modulated by the Number of Genomic
Copies
All verbal memory measures correlated positively with the
number of genomic copies. Duplication carriers outperformed
deletion carriers and control subjects in measures of verbal
long-term memory after adjusting for NVIQ (Figure 1D–F).
Scatter plots showing correlations between verbal long-term
memory measures and NVIQ conﬁrmed that duplication
carriers scored higher than control subjects with similar NVIQ
(Supplemental Figure S3). Regarding verbal short-term mem-
ory, deletion carriers scored signiﬁcantly worse than duplica-
tion carriers (p = .0002) and control subjects (trend, p = .003).
The 16p11.2 locus did not signiﬁcantly affect either short-term
or long-term visuospatial memory.16p11.2 Locus Modulates Inhibition Skills But Not
Working Memory and Planning
Motor and verbal inhibition measures positively correlated to
the number of genomic copies (signiﬁcant for verbal inhibition,
trend for motor inhibition) (Figure 1G–I). Deletion carriers who
performed or tended to perform worse than control subjects
and duplication carriers mainly drove this effect (Table 2). We
did not observe any group differences in working memory and
planning skills (Supplemental Table S5).BiologicalFine Motor Skills. Deletion carriers performed worse than
control subjects in Purdue dominant and nondominant hand
conditions, but there were no signiﬁcant differences in the
bimanual and assembly conditions.
Overall Neuropsychological Proﬁle. To illustrate the
neuropsychological proﬁles of deletion and duplication carriers,
we summarized a sample of the cognitive tasks adjusted and
unadjusted for IQ (Figure 2A, B). Carriers’ data were converted
into Z scores relative to the intrafamilial control subjects to
highlight preserved skills (performance similar to controls after
adjusting for IQ), speciﬁc deﬁcits, and enhanced performances
(lower and higher performances than expected for IQ level).
When adjusted for IQ levels (Figure 2A), the cognitive proﬁle of
deletion carriers showed speciﬁc deﬁcits in language and
inhibition domains, whereas there was no speciﬁc impairment
in the proﬁle of duplication carriers. The latter group showed
enhanced performance in verbal long-term memory. When
results were unadjusted for IQ (Figure 2B), both CNV carriers
showed similar decreased performance in several tasks consis-
tent with their overall IQ level (e.g., verbal comprehension,
working memory, planning, visuospatial skills).
ASD Diagnosis and Additional CNVs. We considered
possible confounders including a diagnosis of ASD (three
deletion carriers and ﬁve duplication carriers) or the presence
of additional deleterious CNVs (one deletion carrier and ﬁve
duplication carriers). The analyses performed after excluding
participants with additional CNVs (Supplemental Table S7) and
analyses excluding participants with ASD led to the same results.
We also considered possible bias secondary to ascertainment
for neurodevelopmental disorders, but proband carriers were not
outperformed by nonproband carriers in any of the cognitive
measures (Supplemental Table S8). Finally, the effect of inher-
itance was tested. In the deletion group, performances of de
novo carriers did not differ from performances of the inherited
carriers (Supplemental Table S9).
Correlation With Brain Anatomy. Whole-brain voxel-
based morphometry analysis showed a positive correlation
between GM volume and the verbal inhibition error rate in
bilateral insula and transverse temporal gyri (Figure 3 and
Supplemental Table S10). Subsequent regression analyses
(left cluster, r2 = .14, p = .007; right cluster, r2 = .24, p = .0003)
revealed that the effect was mainly driven by deletion carriers,
who showed the greatest variance (Figure 3B, C). We report a
trend (uncorrected p value , .001 for all the clusters) for
increased GM volume in the left inferior frontal gyrus, bilateral
superior temporal gyri, and bilateral caudate associated with
deﬁcits in two measures related to phonology: nonword
repetition and reading ﬂuency. Measures of memory did not
covary with any brain structure.DISCUSSION
By assessing carriers of deletion and duplication at the
16p11.2 locus and intrafamilial control subjects, our study
characterizes the effect of this genomic region on severalPsychiatry July 15, 2016; 80:129–139 www.sobp.org/journal 133
Figure 1. Copy number variation and group comparisons on language, memory, and executive measures. Box plots represent language measures of
phonology (A–C), memory (D–F), and executive functions (G–I) in deletion carriers, duplication carriers, and intrafamilial control subjects. Higher scores
translate into better performance except for panel (I), where better performance is represented by a shorter response time. The bold line shows the median,
and the bottom and top of the box show the 25th (quartile 1 [Q1]) and the 75th (quartile 3 [Q3]) percentile, respectively. The upper whisker ends at highest
observed data value within the span from Q3 to Q3 1 1.5 times the interquartile range (Q3–Q1), and lower whisker ends at lowest observed data value within
the span for Q1 to Q1 2 (1.5 * interquartile range). Circles are outliers. Copy number variation effect (one, two, or three copies) and group contrasts are
estimated using a linear mixed model to account for correlated measures within families (A, B, D, G, H, I) and a linear model when only one family member is
included in the analysis (E, F). A nonlinear model was required for panels (C, G, H). We present Z scores when normative data are available in the testing
manual. Otherwise, we present raw scores adjusted for age and sex when appropriate. All scores are adjusted for IQ except for panel (I). Signiﬁcant post hoc
group comparisons (p-corrected threshold = .001) are represented by solid lines with exact p values above, and trends are represented by dashed lines with
exact p values above. CTRL, intrafamilial control subjects; DEL, deletion carriers; DUP, duplication carriers.
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is decreased in both CNVs, speciﬁc cognitive functions
including verbal memory, executive functions, and phonolog-
ical skills show a positive correlation with the number of
genomic copies. The data suggest that duplication carriers
outperform intrafamilial control subjects with the same IQ for
measures of verbal memory and phonology.
A recent study (40) comparing recurrent reciprocal CNVs failed
to identify any correlations between cognitive functions and copy
number state at the 16p11.2 BP4–BP5 and 15q11.2 BP1–BP2
loci. Either the small sample size (n = 7 for 16p11.2 deletion
carriers and duplication carriers, respectively) or the small effect
size (for 15q11.2 BP1–BP2) could explain the lack of signiﬁcant
correlations between cognitive traits and copy number state.134 Biological Psychiatry July 15, 2016; 80:129–139 www.sobp.org/joAlthough linear models show that the number of genomic
copies correlates with performance in several cognitive
domains, our study was underpowered to demonstrate for-
mally that deletion carriers perform worse than control sub-
jects and control subjects perform worse than duplication
carriers for a speciﬁc function. However, the results are
suggestive of such a phenomenon; our analysis of phonologic
skills in a larger independent data set (VIP) supports the
hypothesis that, similar to other complex traits such as body
mass index or brain anatomy, cognitive performances may
covary with molecular mechanisms. Recent ﬁndings on
16p11.2 CNVs mouse models show enhanced memory skills
on a recognition task in duplicated mice compared to wild-
type animals (41). Memory processes have also been linked tournal
Figure 2. Neuropsychological proﬁle in 16p11.2 deletion carriers and
duplication carriers. IQ-adjusted (A) and IQ-unadjusted (B) neuropsycholo-
gical proﬁle of deletion carriers and duplication carriers. The y axis represents
mean cognitive residual scores for deletion carriers (red circles) and duplica-
tion carriers (blue squares) converted into Z scores relative to the intrafamilial
control subjects (black dashed line). Error bars represent SEM. When
appropriate, scores are adjusted for age and sex. The x axis lists one task
per subdomain with the most complete data set: NW repetition (nonword
repetition), Word def (word deﬁnition), Word compr (word comprehension), V
short-term (verbal short-term memory), S short-term (spatial short-term
memory), V long-term (verbal long-term memory), S long-term (spatial long-
term memory), VW memory (verbal working memory), Planning, V inhibition
(verbal inhibition number of success), M inhibition (motor inhibition number of
success), and FSIQ (full-scale intelligence quotient). CTRL, intrafamilial
control subjects; DEL, deletion carriers; DUP, duplication carriers.
Figure 3. Brain structure-behavior correlation analysis between verbal
inhibition score and gray matter (GM) map. (A) Spatial overlap between
negative linear correlation with Stroop score (red) and the neuroanatomic
structures previously identiﬁed as correlating to the number of genomic
copies of the 16p11.2 locus (15). Overlapping clusters are represented in
orange. Maps are thresholded at the p , .05 familywise error corrected level.
Panels (B, C) are scatter plots showing the linear correlation between GM
volume and the Stroop performance at the clusters located in the left insula
(B) and in the right temporal gyri (C) in panel (A). Both panels include the
regression line, correlation coefﬁcient, and p value for each cohort.
CTRL, intrafamilial control subjects; DEL, deletion carriers; DUP, duplication
carriers.
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Psychiatrymechanisms regulating long-term synaptic potentiation and
depression. These synaptic mechanisms require bursts of
local protein synthesis during training and stimulation (42).
Both mammalian target of rapamycin signaling and MAPK3
signaling regulate local synaptic protein synthesis, which
modulates memory performances in murine models (43,44).
The expression levels of MAPK3, which maps within the BP4–
BP5 interval, and of mammalian target of rapamycin pathway
members are signiﬁcantly altered in 16p11.2 CNV carriers (45).
These are good candidate genes underlying or mediating theBiological Psychiatry July 15, 2016; 80:129–139 www.sobp.org/journal 135
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Psychiatrycorrelation between genomic copy number and memory
performances.
Deletion and duplication are strongly and equally associ-
ated with ASD, but our study shows that their cognitive
proﬁles seem to be distinct, highlighting the heterogeneity of
ASD. Our results are consistent with the results of D’Angelo
et al. (7), who observed that the duplication is associated with
a form of low-functioning ASD, whereas cognition in deletion
carriers with ASD is mostly within the normal range. These
results are in line with studies highlighting the potential role of
the CNVs in the speciﬁc patterns of autistic symptoms (46).
For example, there is a long-standing debate on whether ASD
and speciﬁc language impairment arise from similar genetic
bases (47). This study demonstrates that the same genomic
region predisposing to ASD may or may not have a deleterious
effect on structural language depending on the nature of the
mutation. This dissociation between phenotypes observed in
reciprocal CNVs is also corroborated by a recent study
demonstrating that deletions, but not duplications, encom-
passing ASD genes are primarily associated with impairments
in language domains (46).
Special isolated skills and cognitive strengths are also
features deﬁning subgroups of ASD (48). The 16p11.2 dupli-
cation proﬁle is reminiscent of enhanced memory skills also
reported in ASD (49,50) and may represent the ﬁrst example of
an ASD-related genetic predisposition leading to speciﬁc
cognitive strengths compared with control subjects with the
same IQ. The absence of any speciﬁc impairment beyond the
IQ shortfall in duplication carriers at risk for schizophrenia
echoes the nonspeciﬁc cognitive deﬁcit pattern observed in
ﬁrst-episode idiopathic schizophrenia (51,52).
Our results also suggest that neuroanatomic structures
previously deﬁned on the basis of their correlation to number
of genomic copies at the 16p11.2 locus (15) are associated with
alterations in measures of language and verbal inhibition. These
ﬁndings dovetail with previously reported structural ﬁndings
positing the insula as a key player in verbal inhibitory processes
(53,54) as well as the superior temporal gyrus and caudate
nucleus, implicated in speciﬁc language impairment (55–57).
However, larger samples are required to replicate these results
and elucidate any speciﬁc association within groups. The
causal relationship between genomic copies, brain structure,
cognition, and behavior also remains unknown.
Increased volume of the caudate has been observed in
individuals who carry FOXP2 mutations, which is one of the
few genetic forms of speciﬁc language impairment studied to
date (58,59). Language deﬁcits observed in deletion carriers
are largely consistent with a previous study by Hanson et al.
(6) reporting phonological deﬁcits in the context of general
language impairment. Other studies reported the presence of
childhood apraxia of speech, although the exact character-
istics of this deﬁcit are unclear (60–62).
The present study aimed at characterizing the effect of the
16p11.2 locus on speciﬁc cognitive domains by adjusting for
the effect of IQ. We are conﬁdent that our ﬁndings apply to a
broad range of IQ with the exception of very low-functioning
participants who were unable to perform these tasks (11% of
deletion carriers and 27% of duplication carriers). It is unlikely
that the exclusion of individuals with low IQ has biased our
results because a much larger study showed that most136 Biological Psychiatry July 15, 2016; 80:129–139 www.sobp.org/jodeletion carriers and duplication carriers have an IQ .55.
The duplication and the deletion have been associated with a
decrease of approximately 16 points and 22 points of IQ,
respectively (7). This ﬁnding suggests that the subgroup of
very low-functioning carriers may be related to the presence of
additional deleterious genetic variants, which are two to three
times more frequent in 16p11.2 duplication carriers compared
with deletion carriers (7). It is unknown whether low-
functioning carriers represent a distinct subgroup with differ-
ent proﬁles. Most of the probands were ascertained for
neurodevelopmental disorders, which may have also biased
our results. However, stratifying groups in proband and non-
proband carriers does not affect any of the results. The low
frequency of schizophrenia is discordant with the association
reported in prior studies (4). This low frequency is likely to be
due in part to the young age of our probands and the fact that
most of the adults were parents, a fact that selects against a
diagnosis of schizophrenia (63). Follow-up of our probands is
required to estimate accurately the risk of schizophrenia in this
population.
In conclusion, this study suggests that cognitive skills may
be modulated by the number of genomic copies at the
16p11.2 locus in humans. Such effects are clouded by the
global decrease in cognitive functioning that affects both
CNVs. The strength of this study lies in the administration of
an extensive cognitive test battery to both CNV carrier groups
and the intrafamilial control subjects; this allowed us to assess
cognitive function precisely relative to each participant’s
global cognitive level. Further research is warranted to eluci-
date the contribution of speciﬁc genes within the 16p11.2
locus by studying the relationship between expression pat-
terns of these genes and cognitive tasks, brain anatomy, and
brain function. These approaches may ultimately elucidate the
molecular mechanisms that affect speciﬁcally phonological,
verbal memory, and inhibition skills based on the number of
genomic copies. A deeper knowledge of the cognitive
strengths and weaknesses of these patients is critical for
developing cognitive support strategies. Careful language
assessment is recommended in deletion carriers, who might
beneﬁt from more emphasis on the use of visuospatial
processes when learning. In contrast, verbal methods may
improve learning strategies in duplication carriers.ACKNOWLEDGMENTS AND DISCLOSURES
This work was supported by the Leenaards Foundation Prize (SJ, ARey,
NH), Swiss National Science Foundation (SNSF) Sinergia Grant No. CRIS
FN CRSII33-133044 (ARey, SJ), National Center of Competence in
Research Synapsy Project Grant Nos. 320030_135679 and Special Pro-
gram University Medicin 33CM30_140332/1 (BD), Simons Foundation
Autism Research Initiative (SFARI) Grant No. SFARI274424 (ARey), Foun-
dation Parkinson Switzerland (BD), Foundation Synapsis (BD), Human Brain
Project, a European Union initiative (BD), SNSF Grant No. PP00P3_144902/
2 (SJ), a Canada Research Chair (SJ), Jeanne and Jean Louis Lévesque
Foundation (SJ), Center of Excellence in Genomics (Estonian Genome
Center, the University of Tartu [EGCUT] [AMe, ARei, AK, KM]), University of
Tartu Grant No. SP1GVARENG (EGCUT [AMe, ARei, AK, KM]), Estonian
Research Council Grant No. IUT20-60 (EGCUT [AMe, ARei, AK, KM]), Swiss
Scientiﬁc Exchange New Member States Program (KM), and a fellowship
from the doctoral school of the Faculty of Biology and Medicine, University
of Lausanne (MZ). Laboratory for Research in Neuroimaging is supported by
the Roger de Spoelberg and Partridge Foundations. FR received fundingurnal
16p11.2 Copy Number Variation and Cognition
Biological
Psychiatryfrom Agence Nationale (contracts ANR-10-LABX-0087 IEC and ANR-10-
IDEX-0001-02 PSL). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
The Simons Variation in Individuals Project (VIP) work is supported by
SFARI. We thank all the families at the participating Simons VIP sites as well
as the Simons VIP Consortium. We obtained access to phenotypic data on
SFARI Base. Approved researchers can obtain the Simons VIP and SSC
population data sets described in this study by applying at https://base.
sfari.org.
Participants were scanned at the Centre d’Imagerie BioMédicale, which
is a research initiative of the following partners: University of Lausanne,
Swiss Federal Institute of Technology Lausanne, University of Geneva,
Centre Hospitalier Universitaire Vaudois, Hôpitaux Universitaires de Gen-
ève, and the Leenaards and Jeantet Foundations.
We thank all families for their contribution to this work. We thank Anne
Ruef for her helpful advice on the magnetic resonance imaging data
analyses. We thank Zoltan Kutalik for his help with statistical analyses.
The 16p11.2 European consortium collaborators who contributed fam-
ilies to this study include M.-C. Addor, Service of Medical Genetics, Centre
Hospitalier Universitaire Vaudois, Lausanne, Switzerland; J. Andrieux,
Institut de Génétique Médicale, Hôpital Jeanne de Flandre, CHRU de Lille,
Lille, France; B. Arveiler, Université Bordeaux, Maladies Rares: Génétique et
Métabolisme, Service de Génétique Médicale, CHU-Bordeaux, Bordeaux,
France; G. Baujat, Centre de Référence Département de Génétique, Hôpital
Necker-Enfants malades, Paris, France; M. Belﬁore, Laboratoire de Cyto-
génétique, Service de Génétique Médicale, CHUV, Lausanne, Switzerland;
F. Béna, Service of Genetic Medicine, University Hospital of Geneva,
Geneva, Switzerland; F. Bilan, Service de Génétique, CHU-Poitiers, Poitiers,
France; S. Bouquillon, Institut de Génétique Médicale, Hôpital Jeanne de
Flandre, Lille, France; O. Boute, Hôpital Jeanne de Flandre, CHRU de Lille,
Lille, France; J.-L. Bresson, Centre de Génétique Humaine, CHU-Besançon,
Besançon, France; A. Brusco, University of Torino, Department of Medical
Sciences, Turin, Italy; J. Bussat, Service of Medical Genetics, CHUV,
Lausanne, Switzerland; D. Campion, Service de Psychiatrie, Centre Hospi-
talier de Rouvray, Sotteville lès Rouen, France; M. Delrue, Université
Bordeaux, Maladies Rares: Génétique et Métabolisme, Service de Génét-
ique Médicale, CHU-Bordeaux, Bordeaux, France; G. Dervaux, Unité de
Médecine et Chirurgie de l’Obésité, Centre Hospitalier de Béthune,
Béthune, France; R. Etienne, Service de Génétique Médicale, CHUV,
Lausanne, Switzerland; C. Fagerberg, Department of Clinical Genetics,
Odense Universitetshospital, Denmark; F. Fellmann, Service of Medical
Genetics, CHUV, Lausanne, Switzerland; A. Ferrarini, Division of Pediatrics,
San Giovanni Hospital, Bellinzona, Switzerland; S. Fert-Ferrer, UF de
Génétique Chromosomique, Laboratoire de Biologie Médicale, Chambéry,
France; F. Forzano, Genetica Medica, Ospedali Galliera, Genova, Italy; N.
Fournier, Institute of Social and Preventive Medicine, CHUV, Lausanne,
Switzerland; D. Giachino, Genetica Medica, Azienda Ospedaliera Universi-
taria San Luigi Gonzaga Orbassano, Torino, Italy; B. Gilbert-Dussardier,
Service de Génétique Clinique, La Milétrie, CHU Poitiers, Poitiers, France;
O. Guillin, Service Universitaire de Psychiatrie, CHU de Rouen-Centre
Hospitalier du Rouvray, UFR de Médecine et de Pharmacie de Rouen,
Rouen, France; D. Héron, Département de Génétique, Hôpital Pitié-Salpê-
trière, Université Pierre et Marie Curie, Paris, France; M. Holder, Hôpital
Jeanne de Flandre, CHRU de Lille, Lille, France; K. Iglesias, Institute of
Social and Preventive Medicine, CHUV, Lausanne, Switzerland; A. Jac-
quette, Département de Génétique, Groupe Hospitalier Pitié-Salpétrière,
Paris, France; H. Journel, Génétique Médicale, Centre Hospitalier Bretagne
Atlantique, Vannes, France; L. Lazaro, CH Côte-Basque, Service de
Pédiatrie, Bayonne, France; M.-P. Lemaître, Service de Neuropédiatrie,
Centre Hospitalier Régional Universitaire, Lille, France; J. Lespinasse,
Service Génétique Médicale, C.H. Chambéry, Chambéry, France; M.
Malcarne, Laboratory of Human Genetics, Ospedali Galliera, Genova, Italy;
G. Mandrile, Genetica Medica, Azienda Ospedaliera Universitaria San Luigi
Gonzaga Orbassano, Torino, Italy; D. Martinet, Laboratoire de Cytogéné-
tique, Service de Génétique Médicale, CHUV, Lausanne, Switzerland; N.
Migone, Genetica Medica, Struttura Complessa a Direzione Universitaria,
Ospedaliero-Universitaria san Giovanni Battista, Torino, Italy; L. Olivier-
Faivre, Centre de Référence Anomalies du Développement et Syndromes
Malformatifs de l’Interrégion Est, Hôpital d’Enfants, CHU de Dijon et
Université de Bourgogne, Dijon, France; F. Petit, Hôpital Jeanne de Flandre,BiologicalCHRU de Lille, Lille, France; G. Plessis, Service de Génétique Clinique, CHU
Caen, France; F. Prieur, Service de Génétique Médicale, CHU St. Etienne,
St. Etienne, France; G. Ramelli, Department of Pediatrics, San Giovanni
Hospital, Bellinzona, Switzerland; C. Rooryck Thambo, Service de Génét-
ique Médicale, CHU de Bordeaux and Université Bordeaux, Maladies Rares:
Génétique et Métabolisme, Bordeaux, France; D. Sanlaville, Service de
Cytogénétique Constitutionnelle, Hospices Civils de Lyon, CHU de Lyon
and Centre de Recherche en Neuroscience de Lyon, Lyon, France; V.
Siffredi, Service of Medical Genetics, CHUV, Lausanne, Switzerland; J.
Thonney, Department of Psychiatry, CERY Hospital Centre Hospitalier
Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland;
M.M. Van Haelst, Department of Medical Genetics, University Medical
Center, Utrecht, Netherlands; and L. Van Maldergem, Centre de Génétique
Humaine, CHU-Besançon, France.
We thank the coordinators and staff at the Simons VIP sites.
Contributors to the Simons VIP Consortium include Benjamin Aaronson,
Sean Ackerman, Hanalore Alupay, Katy Ankenman, Ayesha Anwar, Con-
stance Atwell, Arthur L. Beaudet, Marta Benedetti, Jessica Berg, Jeffrey
Berman, Leandra N. Berry, Audrey L. Bibb, Lisa Blaskey, Alexandra Bowe,
Jonathan Brennan, Christie M. Brewton, Randy Buckner, Polina Bukshpun,
Jordan Burko, Phil Cali, Bettina Cerban, Yishin Chang, Qixuan Chen,
Maxwell Cheong, Vivian Chow, Zili Chu, Darina Chudnovskaya, Wendy K.
Chung, Lauren Cornew, Corby Dale, Deborah D’Angelo, John Dell, Allison
G. Dempsey, Trent Deschamps, Rachel Earl, James Edgar, Jenna Elgin,
William Faucett, Jennifer Endre Olson, Yolanda L. Evans, Anne Findlay,
Gerald D. Fischbach, Charlie Fisk, Brieana Fregeau, Bill Gaetz, Leah Gaetz,
Silvia Garza, Jennifer Gerdts, Orit Glenn, Sarah E. Gobuty, Rachel Golemb-
ski, Marion Greenup, Kory Heiken, Katherine Hines, Leighton Hinkley, Frank
I. Jackson, Julian Jenkins III, Rita J. Jeremy, Kelly Johnson, Stephen M.
Kanne, Sudha Kessler, Sarah Y. Khan, Matthew Ku, Emily Kuschner, Anna
L. Laakman, Peter Lam, Morgan W. Lasala, David Ledbetter, Hana Lee,
Kevin LeGuerre, Susan Levy, Alyss Lian Cavanagh, Ashlie V. Llorens,
Katherine Loftus Campe, Tracy L. Luks, Elysa J. Marco, Alastair J. Martin,
Christa L. Martin, Stephen Martin, Gabriela Marzano, Christina Masson,
Kathleen E. McGovern, Rebecca McNally Keehn, David T. Miller, Fiona K.
Miller, Timothy J. Moss, Rebecca Murray, Srikantan S. Nagarajan, Kerri P.
Nowell, Julia Owen, Andrea M. Paal, Alan Packer, Patricia Z. Page, Brianna
M. Paul, Alana Peters, Danica Peterson, Annapurna Poduri, Nicholas J.
Pojman, Ken Porche, Monica B. Proud, Saba Qasmieh, Melissa B. Ramocki,
Beau Reilly, Timothy P.L. Roberts, Dennis Shaw, Elliott Sherr, Tuhin Sinha,
Bethanny Smith-Packard, Anne Snow Gallagher, John Spiro, Vivek Swar-
nakar, Tony Thieu, Jennifer Tjernagel, Christina Triantafallou, Roger
Vaughan, Nicole Visyak, Mari Wakahiro, Arianne Wallace, Tracey Ward,
Julia Wenegrat, and Anne Wolken.
The authors report no biomedical ﬁnancial interests or potential conﬂicts
of interest.ARTICLE INFORMATION
From the Service de Génétique Médicale (LH, AMM, BR-H, AP, SM-B, JSB,
SJ), Laboratory for Research in Neuroimaging–Département des Neuro-
sciences Cliniques (BR-H, SM-B, BD), Department of Psychiatry (CF, PC),
CERY Hospital, Department of Child Psychiatry (MB), SUPEA, and Service
of Neuropsychology and Neurorehabilitation (LS), Centre Hospitalier Uni-
versitaire Vaudois and University of Lausanne; Department of Medical
Genetics (AMa), SIB Swiss Institute of Bioinformatics (AMa, JSB), and
Center for Integrative Genomics (KM, ARey), University of Lausanne; Brain
Mind Institute (NH), School of Life Sciences, Ecole Polytechnique Fédérale
de Lausanne, Lausanne, Switzerland; Department of Genetics (AMe, ARei,
KM), United Laboratories, and Children’s Clinic (AK), Department of
Neurology and Neurorehabilitation, Tartu University Hospital, Tartu, Estonia;
Service de Génétique Médicale (BI, CLC, DA), CHU-Nantes; INSERM
UMR957 (CLC), Faculté de Médecine, Nantes; Department of Genetics
and Cytogenetics (CM, BK, MG), Unité fonctionnelle de génétique clinique,
Groupe Hospitalier Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris;
Centre de Référence “Déﬁciences intellectuelles de causes rares” and
Groupe de Recherche Clinique “Déﬁcience intellectuelle et autisme” (CM),
UPMC, Paris, France; Département de Psychiatrie (LM), Université de
Montréal and Hôpital Rivière des Prairies, Montreal, Quebec, Canada;Psychiatry July 15, 2016; 80:129–139 www.sobp.org/journal 137
16p11.2 Copy Number Variation and Cognition
Biological
PsychiatryService de Génétique (MD-F), CHU, Reims; Département de Génétique
(MG), Hôpital Robert Debré, Université Paris VII-Paris Diderot, Paris, France;
Department of Psychiatry and Behavioral Science (RB), University of
Washington, Seattle, Washington; Department of Pediatrics (RPG-K),
Psychology Section, Baylor College of Medicine, Houston, Texas; Depart-
ment of Psychiatry (EH), Boston Children’s Hospital, Harvard Medical
School, Boston, Massachusetts; Clinical Research Associates (LGS), New
York, New York; Laboratoire de Sciences Cognitives et Psycholinguistique
(FR), Département d’Etudes Cognitives, Ecole Normale Supérieure, EHESS,
CNRS, PSL Research University, Paris, France; and Department of Neurol-
ogy (BD), Max-Planck Institute for Human Cognitive and Brain Science,
Leipzig, Germany.
NH is currently afﬁliated with the Gillberg Neuropsychiatry Centre,
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
and Athinoula A. Martinos Center for Biomedical Imaging, Massachussetts
General Hospital, Harvard Medical School, Charlestown, Massachusetts.
SJ is currently afﬁliated with the Département de Pédiatrie, Faculté de
Médecine, Université de Montréal, Montréal, Québec, Canada.
LH and AMM contributed equally to this work.
Address correspondence to Sébastien Jacquemont, M.D., Service de
Génétique, Département de Pédiatrie, 3175 Ch de la Côte-Sainte-Cather-
ine, Montreal, Quebec H3T 1C4, Canada; E-mail: sebastien.jacquemont@
umontreal.ca.
Received Apr 7, 2015; revised Sep 30, 2015; accepted Oct 14, 2015.
Supplementary material cited in this article is available online at http://
dx.doi.org/10.1016/j.biopsych.2015.10.021.
REFERENCES
1. Zufferey F, Sherr EH, Beckmann ND, Hanson E, Maillard AM, Hippo-
lyte L, et al. (2012): A 600 kb deletion syndrome at 16p11.2 leads to
energy imbalance and neuropsychiatric disorders. J Med Genet 49:
660–668.
2. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, et al.
(2011): A copy number variation morbidity map of developmental
delay. Nat Genet 43:838–846.
3. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al.
(2008): Association between microdeletion and microduplication at
16p11.2 and autism. N Engl J Med 358:667–675.
4. McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon
S, et al. (2009): Microduplications of 16p11.2 are associated with
schizophrenia. Nat Genet 41:1223–1227.
5. Green EK, Rees E, Walters JT, Smith KG, Forty L, Grozeva D, et al.
(2016): Copy number variation in bipolar disorder. Mol Psychiatry 21:
89–93.
6. Hanson E, Bernier R, Porche K, Jackson FI, Goin-Kochel RP, Snyder LG,
et al. (2015): The cognitive and behavioral phenotype of the 16p11.2
deletion in a clinically ascertained population. Biol Psychiatry 77:785–793.
7. D’Angelo D, Lebon S, Chen Q, Martin-Brevet S, Green Snyder L,
Hippolyte L, et al. (2016): Deﬁning the effect of the 16p11.2 duplication
on cognition, behavior, and medical comorbidities. JAMA Psychiatry
73:20–30.
8. Hanson E, Nasir RH, Fong A, Lian A, Hundley R, Shen Y, et al. (2010):
Cognitive and behavioral characterization of 16p11.2 deletion syn-
drome. J Dev Behav Pediatr 31:649–657.
9. Shinawi M, Liu P, Kang SH, Shen J, Belmont JW, Scott DA, et al.
(2010): Recurrent reciprocal 16p11.2 rearrangements associated with
global developmental delay, behavioural problems, dysmorphism,
epilepsy, and abnormal head size. J Med Genet 47:332–341.
10. American Psychiatric Association (2000): Diagnostic and Statistical
Manual of Mental Disorders, 4th ed text rev. Washington, DC:
American Psychiatric Association.
11. Jacquemont S, Reymond A, Zufferey F, Harewood L, Walters RG,
Kutalik Z, et al. (2011): Mirror extreme BMI phenotypes associated with
gene dosage at the chromosome 16p11.2 locus. Nature 478:97–102.
12. Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk
K, et al. (2010): Large, rare chromosomal deletions associated with
severe early-onset obesity. Nature 463:666–670.138 Biological Psychiatry July 15, 2016; 80:129–139 www.sobp.org/jo13. Walters RG, Jacquemont S, Valsesia A, de Smith AJ, Martinet D,
Andersson J, et al. (2010): A new highly penetrant form of obesity due
to deletions on chromosome 16p11.2. Nature 463:671–675.
14. Qureshi AY, Mueller S, Snyder AZ, Mukherjee P, Berman JI, Roberts
TP, et al. (2014): Opposing brain differences in 16p11.2 deletion and
duplication carriers. J Neurosci 34:11199–11211.
15. Maillard AM, Ruef A, Pizzagalli F, Migliavacca E, Hippolyte L, Adaszewski
S, et al. (2015): The 16p11.2 locus modulates brain structures common
to autism, schizophrenia and obesity. Mol Psychiatry 20:140–147.
16. Männik K, Magi R, Mace A, Cole B, Guyatt AL, Shihab HA, et al.
(2015): Copy number variations and cognitive phenotypes in unse-
lected populations. JAMA 313:2044–2054.
17. Wechsler D (2004): WPPSI-III Echelle d’Intelligence de Wechsler pour
la Période Pré-Scolaire et Primaire: Troisième édition. Paris: ECPA,
Les Editions du Centre de Psychologie Appliquée.
18. Wechsler D (2005): WISC-IV Echelle d’Intelligence de Wechsler pour
Enfants et Adolescents: Quatrième édition. Paris: ECPA, Les Editions
du Centre de Psychologie Appliquée.
19. Wechsler D (2008): WAIS-III Echelle d’Intelligence de Wechsler pour
Adultes. Paris: ECPA, Les Editions du Centre de Psychologie
Appliquée.
20. Wechsler D (1999): Wechsler Abbreviated Scale of Intelligence. San
Antonio, TX: The Psychological Corporation.
21. Elliot C (2006): Differential Abilities Scale–2nd Edition (DAS-II). San
Antonio, TX: The Psychological Corporation.
22. Tifﬁn J, Asher EJ (1948): The Purdue pegboard; norms and studies of
reliability and validity. J Appl Psychol 32:234–247.
23. Korkman M, Kirk U, Kemp SL, Plaza M (2008): Nepsy, Bilan Neuro-
psychologique de l’enfant: Manuel. Paris: ECPA, les Éditions du
Centre de Psychologie Appliquée.
24. Wagner RK, Torgesen JK, Rashotte CA (1999): Comprehensive Test
of Phonological Processing. Austin, TX: Pro Ed.
25. Dunn L, Thériault-Whalen CM, Dunn L (1993): Peabody Picture
Vocabulary Test–Revised. Toronto: Psycan.
26. Bishop DV (2003): Test for Reception of Grammar. London: Harcourt
Assessment, Psychological Corporation.
27. Boutard C, Claire I, Gretchanovsky L (2010): Le vol du P.C. Isbergues:
Editions Ortho.
28. Allal I, Cheminal-Lancelot R, Devaux M-F, Divry J, Lequette C, Maitrot
C, et al. (2005): R.O.C.: Outil de Repérage Orthographique Collectif.
Grenoble: Cogni-Sciences-IUFM Grenoble.
29. Poitrenaud J, Deweer B, Kalafat M, Van der Linden M (2007): CVLT
Test d’Apprentissage et de Mémoire Verbale (California Verbal Learn-
ing Test: Adaptation Française). Paris: ECPA, Les Editions du Centre
de Psychologie Appliquée.
30. Wechsler D (2001): MEM-III Echelle Clinique de Mémoire: Troisième
édition. Paris: ECPA, Les Editions du Centre de Psychologie Appliquée.
31. Wechsler D, Naglieri J (2009): WNV Echelle non Verbale d’Intelligence
de Wechsler. Paris: ECPA, Les Editions du Centre de Psychologie
Appliquée.
32. Meyers JE, Meyers KR (1995): Rey Complexe Figure Test and
Recognition Trial: Professional Manual. Odessa, FL: Psychological
Assessment Resources.
33. Culbertson WC, Zillmer EA (2009): Tower of London-Drexel University,
2ème edition. Technical Manual. Toronto: Multi-Health Systems Inc.
34. Stroop JR (1935): Studies of interference in serial verbal reactions.
J Exp Psychol 18:643–662.
35. Zimmermann P, Fimm B (2010): Tests d’Évaluation de l’Attention
version 2.2. Herzogenrath: Vera Fimm, Psychologische Testsysteme.
36. Lord C, Rutter M, Le Couteur A (1994): Autism Diagnostic Interview–
Revised: A revised version of a diagnostic interview for caregivers of
individuals with possible pervasive developmental disorders. J Autism
Dev Disord 24:659–685.
37. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC,
et al. (2000): The Autism Diagnostic Observation Schedule–Generic: A
standard measure of social and communication deﬁcits associated
with the spectrum of autism. J Autism Dev Disord 30:205–223.
38. Preisig M, Fenton BT, Matthey ML, Berney A, Ferrero F (1999):
Diagnostic Interview for Genetic Studies (DIGS): Inter-rater andurnal
16p11.2 Copy Number Variation and Cognition
Biological
Psychiatrytest-retest reliability of the French version. Eur Arch Psychiatry Clin
Neurosci 249:174–179.
39. Friston KJ, Tononi G, Reeke GN Jr, Sporns O, Edelman GM (1994):
Value-dependent selection in the brain: Simulation in a synthetic
neural model. Neuroscience 59:229–243.
40. Stefansson H, Meyer-Lindenberg A, Steinberg S, Magnusdottir B,
Morgen K, Arnarsdottir S, et al. (2014): CNVs conferring risk of autism
or schizophrenia affect cognition in controls. Nature 505:361–366.
41. Arbogast T, Ouagazzal A-M, Chevalier C, Kopanitsa M, Aﬁnowi N,
Migliavacca E, et al. (2016): Reciprocal effects on neurocognitive and
metabolic phenotypes in mouse models of 16p11.2 deletion and
duplication syndromes. PLoS Genet 12:e1005709.
42. Rosenberg T, Gal-Ben-Ari S, Dieterich DC, Kreutz MR, Ziv NE,
Gundelﬁnger ED, et al. (2014): The roles of protein expression in
synaptic plasticity and memory consolidation. Front Mol Neurosci 7:86.
43. Costa-Mattioli M, Monteggia LM (2013): mTOR complexes in neuro-
developmental and neuropsychiatric disorders. Nat Neurosci 16:
1537–1543.
44. Stoica L, Zhu PJ, Huang W, Zhou H, Kozma SC, Costa-Mattioli M
(2011): Selective pharmacogenetic inhibition of mammalian target of
Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity
and memory storage. Proc Natl Acad Sci U S A 108:3791–3796.
45. Migliavacca E, Golzio C, Mannik K, Blumenthal I, Oh EC, Harewood L,
et al. (2015): A potential contributory role for ciliary dysfunction
in the 16p11.2 600 kb BP4-BP5 pathology. Am J Hum Genet 96:
784–796.
46. Merikangas AK, Segurado R, Heron EA, Anney RJ, Paterson AD, Cook
EH, et al. (2015): The phenotypic manifestations of rare genic CNVs in
autism spectrum disorder. Mol Psychiatry 20:1366–1372.
47. Lindgren KA, Folstein SE, Tomblin JB, Tager-Flusberg H (2009):
Language and reading abilities of children with autism spectrum
disorders and speciﬁc language impairment and their ﬁrst-degree
relatives. Autism Res 2:22–38.
48. Meilleur AA, Jelenic P, Mottron L (2015): Prevalence of clinically and
empirically deﬁned talents and strengths in autism. J Autism Dev
Disord 45:1354–1367.
49. Jiang YV, Palm BE, DeBolt MC, Goh YS (2015): High-precision visual
long-term memory in children with high-functioning autism. J Abnorm
Psychol 124:447–456.
50. Mottron L, Morasse K, Belleville S (2001): A study of memory
functioning in individuals with autism. J Child Psychol Psychiatry 42:
253–260.Biological51. Mohamed S, Paulsen JS, O’Leary D, Arndt S, Andreasen N (1999):
Generalized cognitive deﬁcits in schizophrenia: A study of ﬁrst-
episode patients. Arch Gen Psychiatry 56:749–754.
52. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al.
(2000): Neuropsychology of ﬁrst-episode schizophrenia: Initial char-
acterization and clinical correlates. Am J Psychiatry 157:549–559.
53. Leung HC, Skudlarski P, Gatenby JC, Peterson BS, Gore JC (2000):
An event-related functional MRI study of the Stroop color word
interference task. Cereb Cortex 10:552–560.
54. Derrfuss J, Brass M, Neumann J, von Cramon DY (2005): Involvement
of the inferior frontal junction in cognitive control: Meta-analyses of
switching and Stroop studies. Hum Brain Mapp 25:22–34.
55. Price CJ (2012): A review and synthesis of the ﬁrst 20 years of PET
and fMRI studies of heard speech, spoken language and reading.
Neuroimage 62:816–847.
56. Howard D, Patterson K, Wise R, Brown WD, Friston K, Weiller C, et al.
(1992): The cortical localization of the lexicons. Positron emission
tomography evidence. Brain 115(pt 6):1769–1782.
57. Giraud AL, Price CJ (2001): The constraints functional neuroimaging
places on classical models of auditory word processing. J Cogn
Neurosci 13:754–765.
58. Lai CS, Gerrelli D, Monaco AP, Fisher SE, Copp AJ (2003): FOXP2
expression during brain development coincides with adult sites of
pathology in a severe speech and language disorder. Brain 126:
2455–2462.
59. Watkins KE, Vargha-Khadem F, Ashburner J, Passingham RE,
Connelly A, Friston KJ, et al. (2002): MRI analysis of an inherited
speech and language disorder: Structural brain abnormalities. Brain
125:465–478.
60. Fedorenko E, Morgan A, Murray E, Cardinaux A, Mei C, Tager-
Flusberg H, et al. (2016): A highly penetrant form of childhood apraxia
of speech due to deletion of 16p11.2. Hum Genet 24:310.
61. Newbury DF, Mari F, Sadighi Akha E, Macdermot KD, Canitano R,
Monaco AP, et al. (2013): Dual copy number variants involving 16p11
and 6q22 in a case of childhood apraxia of speech and pervasive
developmental disorder. Eur J Hum Genet 21:361–365.
62. Raca G, Baas BS, Kirmani S, Lafﬁn JJ, Jackson CA, Strand EA, et al.
(2013): Childhood apraxia of speech (CAS) in two patients with
16p11.2 microdeletion syndrome. Eur J Hum Genet 21:455–459.
63. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A,
Steinberg S, et al. (2008): Large recurrent microdeletions associated
with schizophrenia. Nature 455:232–236.Psychiatry July 15, 2016; 80:129–139 www.sobp.org/journal 139
